In the phase 1b CAMMA 1 trial, cevostamab plus pomalidomide and dexamethasone produced overall response rates of 86.2% to 88.0%.
|Poll|February 22, 2017
Right Upper Quadrant Pain in Abdomen of 60-Year-Old Patient
Author(s)Brian Morse, MD
A 60-year-old woman presents with vague abdominal pain in the right upper quadrant. An ultrasound reveals a gallbladder abnormality. Based on the images from the abdomen MRI, what is the diagnosis?
Advertisement
A 60-year-old woman presents with vague abdominal pain in the right upper quadrant. An ultrasound reveals a gallbladder abnormality. Abdomen magnetic resonance imaging (MRI) from this patient is shown below (coronal T2-weighted and axial postcontrast T1-weighted), with the abnormality depicted with arrows.
What is the diagnosis?
Advertisement
Related to this article
Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis.
Health Canada approved epcoritamab plus lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma, backed by the EPCORE FL-1 trial.
David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
3
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
4
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
5